Abstract: A system for performing over-the-air (OTA) update is disclosed. The system may comprise a first communication interface, an electronic control subsystem of a vehicle, and a gateway. The gateway may be coupled to the electronic control subsystem by way of the first communication interface, receive trigger event information, and detect a trigger condition based on the trigger event information. The gateway may initiate, based on the detection of the trigger condition, a handshake with the electronic control subsystem, verify a set of parameters, and validate a version of a software or a firmware of at least one component of the electronic control subsystem. Based on the verification, the gateway may provide an update file to the electronic control subsystem by way of the first communication interface. The update file is configured to update the software or the firmware for the at least one component.

Abstract: A system for performing over-the-air (OTA) update is disclosed. The system may comprise a first communication interface, an electronic control subsystem of a vehicle, and a gateway. The gateway may be coupled to the electronic control subsystem by way of the first communication interface, receive trigger event information, and detect a trigger condition based on the trigger event information. The gateway may initiate, based on the detection of the trigger condition, a handshake with the electronic control subsystem, verify a set of parameters, and validate a version of a software or a firmware of at least one component of the electronic control subsystem. Based on the verification, the gateway may provide an update file to the electronic control subsystem by way of the first communication interface. The update file is configured to update the software or the firmware for the at least one component.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure provides anti-?4?7 antibodies that bind human ?4?7, their methods of making, and their uses to treat patients with HIV infection.

Abstract: The present disclosure provides anti-?4?7 antibodies that bind human ?4?7, their methods of making, and their uses to treat patients with HIV infection.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Abstract: This disclosure relates to: (a) compounds and salts of formula (I), formula (II), formula (III), and formula (IV), that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides a mechanism for fast routing of data in a Storage Area Network. A protocol interface module (PIM) interfaces with outside networks and the storage devices, such as over fiber channel (FC). The PIM encapsulates received data into a streaming protocol, enabling storage processors to direct data to/from the appropriate physical disk in a similar manner to the directing of network messages over the Internet or other network.

Abstract: This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Abstract: This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Abstract: A programmable lock system is provided for access restricting and user tracking The system includes a lock mechanism, a microcontroller, and an input device for receiving passing information. The microcontroller reads the received passing information and determines whether to unlock the lock mechanism. The system further includes an inlet for receiving an external storage with pre-programmed code. The microcontroller determines whether to access date contained therein base on the pre-programmed code.

Abstract: This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Abstract: Pan-genotypic HCV inhibitors are described. This invention also relates to methods of using these inhibitors to treat HCV infection.

Abstract: Pan-genotypic HCV inhibitors are described. This invention also relates to methods of using these inhibitors to treat HCV infection.

Abstract: The present invention provides a mechanism for fast routing of data in a Storage Area Network. A protocol interface module (PIM) interfaces with outside networks and the storage devices, such as over fiber channel (FC). The PIM encapsulates received data into a streaming protocol, enabling storage processors to direct data to/from the appropriate physical disk in a similar manner to the directing of network messages over the Internet or other network.